Review



egfr sirna  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology egfr sirna
    Egfr Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 112 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/EGFR+siRNA/pm41326761-342-7-9
    Average 93 stars, based on 112 article reviews
    egfr sirna - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Transfection:

    Article Title: Molecular mechanism of the uptake and toxicity of EGF-LipoAgNPs in EGFR-overexpressing cancer cells.
    Article Snippet: The High-Capacity cDNA Reverse Transcription Kit, TaqMan probes, and primers corresponding to the genes encoding ACTB (Hs01060665_g1), EGFR (Hs06634166_s1), SHH (Hs01037584_m1), ATM (Hs01037584_m1), CAV1 (Hs01037584_m1), CLTC (Hs01037584_m1), SH3GLB1 (Hs01037584_m1), AP2M1 (Hs01037584_m1), and NFE2L2 (Hs00765730_m1) were purchased from ThermoFisher (Grand Island, USA). .. EGFR siRNA (sc-29301), Random siRNA, and transfection reagent (sc-29528) were purchased from Santa-Cruz Biotechnology (Texas, USA). ..

    Article Title: Polymorphic Membrane Protein 17G of Chlamydia psittaci Mediated the Binding and Invasion of Bacteria to Host Cells by Interacting and Activating EGFR of the Host.
    Article Snippet: .. C. psittaci Infection To identify the effect ofEGFRonC.psittaci6BCinfection,HeLa229 cells were pretreated with different concentrations of cetuximab (Sigma-Aldrich, Shanghai, China), an anti-EGFR antibody, at 37°C for 2 h. Then, the unbound antibodies were removed from the reaction followed by washing 5 times with PBS, and finally, cell cultures were infected with C. psittaci 6BC at an MOI of 5 and incubated at 37°C for 36-48 h. In another experiment, EGFR in HeLa 229 cells was knocked down via transfection with EGFR siRNA (Santa Cruz, Shanghai, China) according to the manufacturer’s protocol, and the knockdown efficiency was confirmed by Western blots. ..

    Article Title: N-phenylquinazolin-4-amine-based EGFR TKIs suppress pulmonary fibrosis by modulating the EGFR/ERBB3 axis in epithelial–macrophage interaction
    Article Snippet: .. Lipofectamine 2000 (Invitrogen; #11668019) was used as a transfection reagent, and EGFR siRNA (Santa Cruz Biotechnology; #sc-29301), ERBB2 siRNA (Santa Cruz Biotechnology; #sc-29405) ERBB3 siRNA (Santa Cruz Biotechnology; #sc-35327), ERBB4 siRNA (Santa Cruz Biotechnology; #sc-35329), STAT5 siRNA (Santa Cruz Biotechnology; #sc-29495), and control siRNA (Santa Cruz Biotechnology; #sc-37007) were transfected. .. For cytokine treatment, HPAEps were starved with OPTI-MEM (Gibco; #11058021) for 2 h. Next, 1 h after EGFR TKI (1 μM) treatment, the cytokines EGF (30 ng/mL; Sigma-Aldrich; #E9644), EREG (30 ng/mL; R&D System; #1195-EP/CF), and NRG1 (30 ng/mL; Origene; #TP721215) were administered, and prep was performed after 5 min. THP-1 were obtained from Korean Cell Line Bank (#40202).

    Article Title: Collectin-11 promotes fibroblast proliferation and modulates their activation status and extracellular matrix synthesis
    Article Snippet: Biotinylated BSA (Bio-BSA) was from Beijing Psaitong Biotechnology. .. BSA and L-fucose were sourced from Sigma-Aldrich, EGFR siRNA (sc-29302, Santa Cruz), TGFRII siRNA (Suzhou GenePharma), control siRNA (sc-37007, Santa Cruz), siRNA Transfection Medium (sc-36868, Santa Cruz), siRNA Transfection Reagent (sc-29528, Santa Cruz). ..

    Article Title: N-phenylquinazolin-4-amine-based EGFR TKIs suppress pulmonary fibrosis by modulating the EGFR/ERBB3 axis in epithelial-macrophage interaction.
    Article Snippet: .. Communications Biology | (2025) 8:1723 12 and EGFR siRNA (Santa Cruz Biotechnology; #sc-29301), ERBB2 siRNA (Santa Cruz Biotechnology; #sc-29405) ERBB3 siRNA (Santa Cruz Biotechnology; #sc-35327), ERBB4 siRNA (Santa Cruz Biotechnology; #sc35329), STAT5 siRNA (Santa Cruz Biotechnology; #sc-29495), and control siRNA (Santa Cruz Biotechnology; #sc-37007) were transfected. .. For cytokine treatment, HPAEps were starved with OPTI-MEM (Gibco; #11058021) for 2 h.Next, 1 h after EGFRTKI (1 μM) treatment, the cytokinesEGF (30 ng/mL; Sigma-Aldrich; #E9644), EREG(30 ng/mL;R&D System; #1195-EP/CF), and NRG1 (30 ng/mL; Origene; #TP721215) were administered, and prep was performed after 5min.

    Infection:

    Article Title: Polymorphic Membrane Protein 17G of Chlamydia psittaci Mediated the Binding and Invasion of Bacteria to Host Cells by Interacting and Activating EGFR of the Host.
    Article Snippet: .. C. psittaci Infection To identify the effect ofEGFRonC.psittaci6BCinfection,HeLa229 cells were pretreated with different concentrations of cetuximab (Sigma-Aldrich, Shanghai, China), an anti-EGFR antibody, at 37°C for 2 h. Then, the unbound antibodies were removed from the reaction followed by washing 5 times with PBS, and finally, cell cultures were infected with C. psittaci 6BC at an MOI of 5 and incubated at 37°C for 36-48 h. In another experiment, EGFR in HeLa 229 cells was knocked down via transfection with EGFR siRNA (Santa Cruz, Shanghai, China) according to the manufacturer’s protocol, and the knockdown efficiency was confirmed by Western blots. ..

    Incubation:

    Article Title: Polymorphic Membrane Protein 17G of Chlamydia psittaci Mediated the Binding and Invasion of Bacteria to Host Cells by Interacting and Activating EGFR of the Host.
    Article Snippet: .. C. psittaci Infection To identify the effect ofEGFRonC.psittaci6BCinfection,HeLa229 cells were pretreated with different concentrations of cetuximab (Sigma-Aldrich, Shanghai, China), an anti-EGFR antibody, at 37°C for 2 h. Then, the unbound antibodies were removed from the reaction followed by washing 5 times with PBS, and finally, cell cultures were infected with C. psittaci 6BC at an MOI of 5 and incubated at 37°C for 36-48 h. In another experiment, EGFR in HeLa 229 cells was knocked down via transfection with EGFR siRNA (Santa Cruz, Shanghai, China) according to the manufacturer’s protocol, and the knockdown efficiency was confirmed by Western blots. ..

    Knockdown:

    Article Title: Polymorphic Membrane Protein 17G of Chlamydia psittaci Mediated the Binding and Invasion of Bacteria to Host Cells by Interacting and Activating EGFR of the Host.
    Article Snippet: .. C. psittaci Infection To identify the effect ofEGFRonC.psittaci6BCinfection,HeLa229 cells were pretreated with different concentrations of cetuximab (Sigma-Aldrich, Shanghai, China), an anti-EGFR antibody, at 37°C for 2 h. Then, the unbound antibodies were removed from the reaction followed by washing 5 times with PBS, and finally, cell cultures were infected with C. psittaci 6BC at an MOI of 5 and incubated at 37°C for 36-48 h. In another experiment, EGFR in HeLa 229 cells was knocked down via transfection with EGFR siRNA (Santa Cruz, Shanghai, China) according to the manufacturer’s protocol, and the knockdown efficiency was confirmed by Western blots. ..

    Western Blot:

    Article Title: Polymorphic Membrane Protein 17G of Chlamydia psittaci Mediated the Binding and Invasion of Bacteria to Host Cells by Interacting and Activating EGFR of the Host.
    Article Snippet: .. C. psittaci Infection To identify the effect ofEGFRonC.psittaci6BCinfection,HeLa229 cells were pretreated with different concentrations of cetuximab (Sigma-Aldrich, Shanghai, China), an anti-EGFR antibody, at 37°C for 2 h. Then, the unbound antibodies were removed from the reaction followed by washing 5 times with PBS, and finally, cell cultures were infected with C. psittaci 6BC at an MOI of 5 and incubated at 37°C for 36-48 h. In another experiment, EGFR in HeLa 229 cells was knocked down via transfection with EGFR siRNA (Santa Cruz, Shanghai, China) according to the manufacturer’s protocol, and the knockdown efficiency was confirmed by Western blots. ..

    Expressing:

    Article Title: Tyrosine sulphation of CXCR4 induces the migration of fibroblast in OSF.
    Article Snippet: Oral submucous fibrosis (OSF) is a potentially cancerous oral mucosal disease, which is generally considered to be caused by areca nut chewing and characterised by progressive accumulation of collagen fibres in the lamina propria and the underlying submucosal layer (Shruti et al., 2009).. Fibrotic remodelling is a common pathological abnormality in OSF development, while fibroblasts (FBs) are the key cell type for the pathological process (Isaac et al., 2008).. In fibrotic progression, FBs can be induced to migrate and recruit into the provisional matrix, followed by deposition and production of excessive extracellular matrix under inflammatory stimulation.

    Plasmid Preparation:

    Article Title: Tyrosine sulphation of CXCR4 induces the migration of fibroblast in OSF.
    Article Snippet: Oral submucous fibrosis (OSF) is a potentially cancerous oral mucosal disease, which is generally considered to be caused by areca nut chewing and characterised by progressive accumulation of collagen fibres in the lamina propria and the underlying submucosal layer (Shruti et al., 2009).. Fibrotic remodelling is a common pathological abnormality in OSF development, while fibroblasts (FBs) are the key cell type for the pathological process (Isaac et al., 2008).. In fibrotic progression, FBs can be induced to migrate and recruit into the provisional matrix, followed by deposition and production of excessive extracellular matrix under inflammatory stimulation.

    Construct:

    Article Title: Tyrosine sulphation of CXCR4 induces the migration of fibroblast in OSF.
    Article Snippet: Oral submucous fibrosis (OSF) is a potentially cancerous oral mucosal disease, which is generally considered to be caused by areca nut chewing and characterised by progressive accumulation of collagen fibres in the lamina propria and the underlying submucosal layer (Shruti et al., 2009).. Fibrotic remodelling is a common pathological abnormality in OSF development, while fibroblasts (FBs) are the key cell type for the pathological process (Isaac et al., 2008).. In fibrotic progression, FBs can be induced to migrate and recruit into the provisional matrix, followed by deposition and production of excessive extracellular matrix under inflammatory stimulation.

    Cloning:

    Article Title: Tyrosine sulphation of CXCR4 induces the migration of fibroblast in OSF.
    Article Snippet: Oral submucous fibrosis (OSF) is a potentially cancerous oral mucosal disease, which is generally considered to be caused by areca nut chewing and characterised by progressive accumulation of collagen fibres in the lamina propria and the underlying submucosal layer (Shruti et al., 2009).. Fibrotic remodelling is a common pathological abnormality in OSF development, while fibroblasts (FBs) are the key cell type for the pathological process (Isaac et al., 2008).. In fibrotic progression, FBs can be induced to migrate and recruit into the provisional matrix, followed by deposition and production of excessive extracellular matrix under inflammatory stimulation.

    Control:

    Article Title: Glycopolymer-Cell-Penetrating Peptide (CPP) Conjugates for Efficient Epidermal Growth Factor Receptor (EGFR) Silencing.
    Article Snippet: .. Control, fluorescein isothiocyanate FITC-conjugated control siRNA, EGFR siRNA, and primary antibody (rabbit poyclonal EGFR specific IgG) were ordered from Santa Cruz Biotechnology. .. HRP-conjugated secondary antibody (Anti-rabbi IgG) was obtained from Promega Corporation.

    Article Title: N-phenylquinazolin-4-amine-based EGFR TKIs suppress pulmonary fibrosis by modulating the EGFR/ERBB3 axis in epithelial–macrophage interaction
    Article Snippet: .. Lipofectamine 2000 (Invitrogen; #11668019) was used as a transfection reagent, and EGFR siRNA (Santa Cruz Biotechnology; #sc-29301), ERBB2 siRNA (Santa Cruz Biotechnology; #sc-29405) ERBB3 siRNA (Santa Cruz Biotechnology; #sc-35327), ERBB4 siRNA (Santa Cruz Biotechnology; #sc-35329), STAT5 siRNA (Santa Cruz Biotechnology; #sc-29495), and control siRNA (Santa Cruz Biotechnology; #sc-37007) were transfected. .. For cytokine treatment, HPAEps were starved with OPTI-MEM (Gibco; #11058021) for 2 h. Next, 1 h after EGFR TKI (1 μM) treatment, the cytokines EGF (30 ng/mL; Sigma-Aldrich; #E9644), EREG (30 ng/mL; R&D System; #1195-EP/CF), and NRG1 (30 ng/mL; Origene; #TP721215) were administered, and prep was performed after 5 min. THP-1 were obtained from Korean Cell Line Bank (#40202).

    Article Title: Collectin-11 promotes fibroblast proliferation and modulates their activation status and extracellular matrix synthesis
    Article Snippet: Biotinylated BSA (Bio-BSA) was from Beijing Psaitong Biotechnology. .. BSA and L-fucose were sourced from Sigma-Aldrich, EGFR siRNA (sc-29302, Santa Cruz), TGFRII siRNA (Suzhou GenePharma), control siRNA (sc-37007, Santa Cruz), siRNA Transfection Medium (sc-36868, Santa Cruz), siRNA Transfection Reagent (sc-29528, Santa Cruz). ..

    Article Title: N-phenylquinazolin-4-amine-based EGFR TKIs suppress pulmonary fibrosis by modulating the EGFR/ERBB3 axis in epithelial-macrophage interaction.
    Article Snippet: .. Communications Biology | (2025) 8:1723 12 and EGFR siRNA (Santa Cruz Biotechnology; #sc-29301), ERBB2 siRNA (Santa Cruz Biotechnology; #sc-29405) ERBB3 siRNA (Santa Cruz Biotechnology; #sc-35327), ERBB4 siRNA (Santa Cruz Biotechnology; #sc35329), STAT5 siRNA (Santa Cruz Biotechnology; #sc-29495), and control siRNA (Santa Cruz Biotechnology; #sc-37007) were transfected. .. For cytokine treatment, HPAEps were starved with OPTI-MEM (Gibco; #11058021) for 2 h.Next, 1 h after EGFRTKI (1 μM) treatment, the cytokinesEGF (30 ng/mL; Sigma-Aldrich; #E9644), EREG(30 ng/mL;R&D System; #1195-EP/CF), and NRG1 (30 ng/mL; Origene; #TP721215) were administered, and prep was performed after 5min.



    Similar Products

    86
    Genechem egfr single hairpin rna shrna
    Knockdown of epidermal growth factor receptor blocked the positive effects of epiregulin on migration, chemotaxis, and osteogenic potential of mouse bone marrow stem cells under inflammatory conditions. A: Quantitative analysis of quantitative real-time polymerase chain reaction showed that the transcription of epidermal growth factor receptor ( <t>Egfr</t> ) mRNA was decreased in the EGFR single hairpin <t>RNA</t> <t>(shRNA)</t> group ( n = 3, Student’s t -test). Glyceraldehyde 3-phosphate dehydrogenase ( Gapdh ) was used as an internal control; B: Expression of EGFR was revealed in mouse bone marrow stem cells by western blotting. GAPDH was used as the internal control; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 50 μm; G: Alizarin Red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) was revealed in mouse bone marrow stem cells that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation. a P ≤ 0.05; b P ≤ 0.01. EREG: Epiregulin.
    Egfr Single Hairpin Rna Shrna, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/guide+rna+sequences/pmc12968805-67-0-13
    Average 86 stars, based on 1 article reviews
    egfr single hairpin rna shrna - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti egfr
    Knockdown of epidermal growth factor receptor blocked the positive effects of epiregulin on migration, chemotaxis, and osteogenic potential of mouse bone marrow stem cells under inflammatory conditions. A: Quantitative analysis of quantitative real-time polymerase chain reaction showed that the transcription of epidermal growth factor receptor ( <t>Egfr</t> ) mRNA was decreased in the EGFR single hairpin <t>RNA</t> <t>(shRNA)</t> group ( n = 3, Student’s t -test). Glyceraldehyde 3-phosphate dehydrogenase ( Gapdh ) was used as an internal control; B: Expression of EGFR was revealed in mouse bone marrow stem cells by western blotting. GAPDH was used as the internal control; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 50 μm; G: Alizarin Red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) was revealed in mouse bone marrow stem cells that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation. a P ≤ 0.05; b P ≤ 0.01. EREG: Epiregulin.
    Anti Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/SignalSilence+Rheb+siRNA+I/pm41430602-51-12-29
    Average 94 stars, based on 1 article reviews
    anti egfr - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology egfr sirna
    Knockdown of epidermal growth factor receptor blocked the positive effects of epiregulin on migration, chemotaxis, and osteogenic potential of mouse bone marrow stem cells under inflammatory conditions. A: Quantitative analysis of quantitative real-time polymerase chain reaction showed that the transcription of epidermal growth factor receptor ( <t>Egfr</t> ) mRNA was decreased in the EGFR single hairpin <t>RNA</t> <t>(shRNA)</t> group ( n = 3, Student’s t -test). Glyceraldehyde 3-phosphate dehydrogenase ( Gapdh ) was used as an internal control; B: Expression of EGFR was revealed in mouse bone marrow stem cells by western blotting. GAPDH was used as the internal control; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 50 μm; G: Alizarin Red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) was revealed in mouse bone marrow stem cells that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation. a P ≤ 0.05; b P ≤ 0.01. EREG: Epiregulin.
    Egfr Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/EGFR+siRNA/pm41326761-342-7-9
    Average 93 stars, based on 1 article reviews
    egfr sirna - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc egfr sirna
    <t>EGFR</t> inhibitors reversibly increase LGR5 expression in CRC cells independent of mutation status (A) Western blot of endogenous EGFR and LGR5 expression in a panel of CRC cell lines and patient-derived xenograft (PDX) models XST-GI-010 and CRC-001. (B) EGFR and LGR5 RNA-seq expression data from Cancer Cell Line Encyclopedia (CCLE). Values are read per kilobase of transcript per million (RPKM). Western blots and quantification of LGR5 protein fold changes normalized to actin. (C–E) LIM1215, LoVo, and SW620 cells following 48 h treatment with a panel of EGFR- and HER2-targeting mAbs (3 μg/mL) and TKIs (1 μM), (D) 5 μg/mL CTX over indicated time course, and (E) LIM1215, LoVo, and DLD-1 cells following 15 min CTX treatment and subsequent washout for indicated time course. Data presented as mean +/- SD. (F) Immunocytochemistry staining of total (permeabilized) and surface (non-permeabilized) LGR5 in LoVo cells treated for 15 min with vehicle or 5 μg/mL CTX. Scale bars: 20 μ M (G and H) Western blot and quantification of LGR5 protein fold changes normalized to actin (G) cycloheximide (CHX, 30 μg/mL) chase for 4 or 24 h performed in LoVo cells pre-treated for 15 min with vehicle or 5 μg/mL CTX (s, short exposure; l, long exposure) and (H) LoVo cells pre-treated for 15 min with 0.1 μM bafilomycin A1 or 10 μM MG132 to inhibit lysosomal or proteasomal degradation, respectively, in the presence or absence of 5 μg/mL CTX. Data presented as mean +/- SD. See also ; and .
    Egfr Sirna, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/SignalSilence+EGF+Receptor+siRNA+I/pmc12629807-440-34-36
    Average 93 stars, based on 1 article reviews
    egfr sirna - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    86
    Obio Technology Corp Ltd mouse egfr shrna lentiviruses
    <t>EGFR</t> inhibitors reversibly increase LGR5 expression in CRC cells independent of mutation status (A) Western blot of endogenous EGFR and LGR5 expression in a panel of CRC cell lines and patient-derived xenograft (PDX) models XST-GI-010 and CRC-001. (B) EGFR and LGR5 RNA-seq expression data from Cancer Cell Line Encyclopedia (CCLE). Values are read per kilobase of transcript per million (RPKM). Western blots and quantification of LGR5 protein fold changes normalized to actin. (C–E) LIM1215, LoVo, and SW620 cells following 48 h treatment with a panel of EGFR- and HER2-targeting mAbs (3 μg/mL) and TKIs (1 μM), (D) 5 μg/mL CTX over indicated time course, and (E) LIM1215, LoVo, and DLD-1 cells following 15 min CTX treatment and subsequent washout for indicated time course. Data presented as mean +/- SD. (F) Immunocytochemistry staining of total (permeabilized) and surface (non-permeabilized) LGR5 in LoVo cells treated for 15 min with vehicle or 5 μg/mL CTX. Scale bars: 20 μ M (G and H) Western blot and quantification of LGR5 protein fold changes normalized to actin (G) cycloheximide (CHX, 30 μg/mL) chase for 4 or 24 h performed in LoVo cells pre-treated for 15 min with vehicle or 5 μg/mL CTX (s, short exposure; l, long exposure) and (H) LoVo cells pre-treated for 15 min with 0.1 μM bafilomycin A1 or 10 μM MG132 to inhibit lysosomal or proteasomal degradation, respectively, in the presence or absence of 5 μg/mL CTX. Data presented as mean +/- SD. See also ; and .
    Mouse Egfr Shrna Lentiviruses, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/ifnar1+mouse+sirna/pm41046886-64-6-13
    Average 86 stars, based on 1 article reviews
    mouse egfr shrna lentiviruses - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology human lentiviral egfr shrna
    <t>EGFR</t> inhibitors reversibly increase LGR5 expression in CRC cells independent of mutation status (A) Western blot of endogenous EGFR and LGR5 expression in a panel of CRC cell lines and patient-derived xenograft (PDX) models XST-GI-010 and CRC-001. (B) EGFR and LGR5 RNA-seq expression data from Cancer Cell Line Encyclopedia (CCLE). Values are read per kilobase of transcript per million (RPKM). Western blots and quantification of LGR5 protein fold changes normalized to actin. (C–E) LIM1215, LoVo, and SW620 cells following 48 h treatment with a panel of EGFR- and HER2-targeting mAbs (3 μg/mL) and TKIs (1 μM), (D) 5 μg/mL CTX over indicated time course, and (E) LIM1215, LoVo, and DLD-1 cells following 15 min CTX treatment and subsequent washout for indicated time course. Data presented as mean +/- SD. (F) Immunocytochemistry staining of total (permeabilized) and surface (non-permeabilized) LGR5 in LoVo cells treated for 15 min with vehicle or 5 μg/mL CTX. Scale bars: 20 μ M (G and H) Western blot and quantification of LGR5 protein fold changes normalized to actin (G) cycloheximide (CHX, 30 μg/mL) chase for 4 or 24 h performed in LoVo cells pre-treated for 15 min with vehicle or 5 μg/mL CTX (s, short exposure; l, long exposure) and (H) LoVo cells pre-treated for 15 min with 0.1 μM bafilomycin A1 or 10 μM MG132 to inhibit lysosomal or proteasomal degradation, respectively, in the presence or absence of 5 μg/mL CTX. Data presented as mean +/- SD. See also ; and .
    Human Lentiviral Egfr Shrna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/egfr+sirna/EGFR+siRNA/pm40957723-32-0-20
    Average 93 stars, based on 1 article reviews
    human lentiviral egfr shrna - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Knockdown of epidermal growth factor receptor blocked the positive effects of epiregulin on migration, chemotaxis, and osteogenic potential of mouse bone marrow stem cells under inflammatory conditions. A: Quantitative analysis of quantitative real-time polymerase chain reaction showed that the transcription of epidermal growth factor receptor ( Egfr ) mRNA was decreased in the EGFR single hairpin RNA (shRNA) group ( n = 3, Student’s t -test). Glyceraldehyde 3-phosphate dehydrogenase ( Gapdh ) was used as an internal control; B: Expression of EGFR was revealed in mouse bone marrow stem cells by western blotting. GAPDH was used as the internal control; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 50 μm; G: Alizarin Red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) was revealed in mouse bone marrow stem cells that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation. a P ≤ 0.05; b P ≤ 0.01. EREG: Epiregulin.

    Journal: World Journal of Stem Cells

    Article Title: Epiregulin enhances periodontal tissue regeneration by promoting bone marrow mesenchymal stem cell functions under inflammatory niches

    doi: 10.4252/wjsc.v18.i2.114032

    Figure Lengend Snippet: Knockdown of epidermal growth factor receptor blocked the positive effects of epiregulin on migration, chemotaxis, and osteogenic potential of mouse bone marrow stem cells under inflammatory conditions. A: Quantitative analysis of quantitative real-time polymerase chain reaction showed that the transcription of epidermal growth factor receptor ( Egfr ) mRNA was decreased in the EGFR single hairpin RNA (shRNA) group ( n = 3, Student’s t -test). Glyceraldehyde 3-phosphate dehydrogenase ( Gapdh ) was used as an internal control; B: Expression of EGFR was revealed in mouse bone marrow stem cells by western blotting. GAPDH was used as the internal control; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 50 μm; G: Alizarin Red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) was revealed in mouse bone marrow stem cells that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation. a P ≤ 0.05; b P ≤ 0.01. EREG: Epiregulin.

    Article Snippet: EGFR single hairpin RNA (shRNA) and control shRNA (Ctrl sh) were purchased from GeneChem, Inc. (Shanghai, China).

    Techniques: Knockdown, Migration, Chemotaxis Assay, Real-time Polymerase Chain Reaction, shRNA, Control, Expressing, Western Blot, Staining, Cell Culture, Standard Deviation

    Epiregulin activated the epidermal growth factor receptor-extracellular signal-regulated kinase 1/2 signaling pathway to promote migration, chemotaxis, and osteogenic differentiation of mouse bone marrow stem cells under inflammatory conditions. A: Expression of mitogen-activated protein kinase signaling pathway were revealed in mouse bone marrow stem cells (mBMSCs) that were cultured in the inflammatory condition by western blotting. β-actin was used as the internal control; B: Expression of phosphorylated extracellular signal-regulated kinase (p-ERK) and ERK were detected in mBMSCs that were cultured in the inflammation condition by western blotting; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 100 μm; G: Alizarin red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) were revealed in mBMSCs that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation ( n = 3). a P ≤ 0.05; b P ≤ 0.01. EGFR: Epidermal growth factor receptor; EREG: Epiregulin; JNK: C-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase.

    Journal: World Journal of Stem Cells

    Article Title: Epiregulin enhances periodontal tissue regeneration by promoting bone marrow mesenchymal stem cell functions under inflammatory niches

    doi: 10.4252/wjsc.v18.i2.114032

    Figure Lengend Snippet: Epiregulin activated the epidermal growth factor receptor-extracellular signal-regulated kinase 1/2 signaling pathway to promote migration, chemotaxis, and osteogenic differentiation of mouse bone marrow stem cells under inflammatory conditions. A: Expression of mitogen-activated protein kinase signaling pathway were revealed in mouse bone marrow stem cells (mBMSCs) that were cultured in the inflammatory condition by western blotting. β-actin was used as the internal control; B: Expression of phosphorylated extracellular signal-regulated kinase (p-ERK) and ERK were detected in mBMSCs that were cultured in the inflammation condition by western blotting; C and D: Scratch-simulated wound migration assay results ( n = 3, one-way analysis of variance [ANOVA]). Scale bar: 500 μm; E and F: Transwell chemotaxis assay results ( n = 3, one-way ANOVA). Scale bar: 100 μm; G: Alizarin red staining; H: Expression of osterix (OSX) and osteocalcin (OCN) were revealed in mBMSCs that were cultured in the inflammatory condition by western blotting. Error bars represent standard deviation ( n = 3). a P ≤ 0.05; b P ≤ 0.01. EGFR: Epidermal growth factor receptor; EREG: Epiregulin; JNK: C-Jun N-terminal kinase; MAPK: Mitogen-activated protein kinase.

    Article Snippet: EGFR single hairpin RNA (shRNA) and control shRNA (Ctrl sh) were purchased from GeneChem, Inc. (Shanghai, China).

    Techniques: Migration, Chemotaxis Assay, Expressing, Cell Culture, Western Blot, Control, Staining, Standard Deviation

    EGFR inhibitors reversibly increase LGR5 expression in CRC cells independent of mutation status (A) Western blot of endogenous EGFR and LGR5 expression in a panel of CRC cell lines and patient-derived xenograft (PDX) models XST-GI-010 and CRC-001. (B) EGFR and LGR5 RNA-seq expression data from Cancer Cell Line Encyclopedia (CCLE). Values are read per kilobase of transcript per million (RPKM). Western blots and quantification of LGR5 protein fold changes normalized to actin. (C–E) LIM1215, LoVo, and SW620 cells following 48 h treatment with a panel of EGFR- and HER2-targeting mAbs (3 μg/mL) and TKIs (1 μM), (D) 5 μg/mL CTX over indicated time course, and (E) LIM1215, LoVo, and DLD-1 cells following 15 min CTX treatment and subsequent washout for indicated time course. Data presented as mean +/- SD. (F) Immunocytochemistry staining of total (permeabilized) and surface (non-permeabilized) LGR5 in LoVo cells treated for 15 min with vehicle or 5 μg/mL CTX. Scale bars: 20 μ M (G and H) Western blot and quantification of LGR5 protein fold changes normalized to actin (G) cycloheximide (CHX, 30 μg/mL) chase for 4 or 24 h performed in LoVo cells pre-treated for 15 min with vehicle or 5 μg/mL CTX (s, short exposure; l, long exposure) and (H) LoVo cells pre-treated for 15 min with 0.1 μM bafilomycin A1 or 10 μM MG132 to inhibit lysosomal or proteasomal degradation, respectively, in the presence or absence of 5 μg/mL CTX. Data presented as mean +/- SD. See also ; and .

    Journal: Cell Reports Medicine

    Article Title: Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

    doi: 10.1016/j.xcrm.2025.102363

    Figure Lengend Snippet: EGFR inhibitors reversibly increase LGR5 expression in CRC cells independent of mutation status (A) Western blot of endogenous EGFR and LGR5 expression in a panel of CRC cell lines and patient-derived xenograft (PDX) models XST-GI-010 and CRC-001. (B) EGFR and LGR5 RNA-seq expression data from Cancer Cell Line Encyclopedia (CCLE). Values are read per kilobase of transcript per million (RPKM). Western blots and quantification of LGR5 protein fold changes normalized to actin. (C–E) LIM1215, LoVo, and SW620 cells following 48 h treatment with a panel of EGFR- and HER2-targeting mAbs (3 μg/mL) and TKIs (1 μM), (D) 5 μg/mL CTX over indicated time course, and (E) LIM1215, LoVo, and DLD-1 cells following 15 min CTX treatment and subsequent washout for indicated time course. Data presented as mean +/- SD. (F) Immunocytochemistry staining of total (permeabilized) and surface (non-permeabilized) LGR5 in LoVo cells treated for 15 min with vehicle or 5 μg/mL CTX. Scale bars: 20 μ M (G and H) Western blot and quantification of LGR5 protein fold changes normalized to actin (G) cycloheximide (CHX, 30 μg/mL) chase for 4 or 24 h performed in LoVo cells pre-treated for 15 min with vehicle or 5 μg/mL CTX (s, short exposure; l, long exposure) and (H) LoVo cells pre-treated for 15 min with 0.1 μM bafilomycin A1 or 10 μM MG132 to inhibit lysosomal or proteasomal degradation, respectively, in the presence or absence of 5 μg/mL CTX. Data presented as mean +/- SD. See also ; and .

    Article Snippet: Chemical inhibitors, ligands, and siRNA used include: gefitinib (Cat# HY-50895); lapatinib (Cat# GW572016 ); nimotuzumab (Cat# HY-P9968); and U0126 (Cat# HY-12031A) from MedChemExpress; trametinib (Selleck Cat# GSK1120212); CHX (Selleck Cat#S7418); EGF (Gibco Cat# PMG8043); EGFR siRNA (Cell Signaling Technology Cat# 6480); MISSION negative control siRNA (Sigma Cat# SIC001).

    Techniques: Expressing, Mutagenesis, Western Blot, Derivative Assay, RNA Sequencing, Immunocytochemistry, Staining

    LGR5 levels are reduced simultaneously with loss of EGFR expression in CRC cells Western blot and quantification following (A) 72 h treatment with 100 nM EGFR siRNA or non-targeting control siRNA in LIM1215, LoVo, and DLD-1 cells, (B) treatment with 30 ng/mL EGF for 8 or 24 h in LoVo cells, (C) 48 h treatment with 1 ng/mL EGF in LIM1215 and DLD-1 cells, and (D) 48 h treatment of LoVo, DLD-1, DLD-1 shLGR5, and SW620 cells with increasing doses of MEK1/2 inhibitor trametinib. EGFR and LGR5 protein fold changes were normalized to actin, and p-ERK/2 protein fold change was normalized to total ERK1/2 for western blot quantification. Data presented as mean +/- SD. See also .

    Journal: Cell Reports Medicine

    Article Title: Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

    doi: 10.1016/j.xcrm.2025.102363

    Figure Lengend Snippet: LGR5 levels are reduced simultaneously with loss of EGFR expression in CRC cells Western blot and quantification following (A) 72 h treatment with 100 nM EGFR siRNA or non-targeting control siRNA in LIM1215, LoVo, and DLD-1 cells, (B) treatment with 30 ng/mL EGF for 8 or 24 h in LoVo cells, (C) 48 h treatment with 1 ng/mL EGF in LIM1215 and DLD-1 cells, and (D) 48 h treatment of LoVo, DLD-1, DLD-1 shLGR5, and SW620 cells with increasing doses of MEK1/2 inhibitor trametinib. EGFR and LGR5 protein fold changes were normalized to actin, and p-ERK/2 protein fold change was normalized to total ERK1/2 for western blot quantification. Data presented as mean +/- SD. See also .

    Article Snippet: Chemical inhibitors, ligands, and siRNA used include: gefitinib (Cat# HY-50895); lapatinib (Cat# GW572016 ); nimotuzumab (Cat# HY-P9968); and U0126 (Cat# HY-12031A) from MedChemExpress; trametinib (Selleck Cat# GSK1120212); CHX (Selleck Cat#S7418); EGF (Gibco Cat# PMG8043); EGFR siRNA (Cell Signaling Technology Cat# 6480); MISSION negative control siRNA (Sigma Cat# SIC001).

    Techniques: Expressing, Western Blot, Control

    EGFR interaction with LGR5 is enhanced by CTX (A and B) Co-immunoprecipitation (coIP) experiments with EGFR antibody or IgG isotype control shows that (A) recombinant LGR5 in 293T-LGR5 cells and (B) endogenous LGR5 in LoVo cells specifically interact with endogenous EGFR. (C) CoIP experiment with LGR5 mAb in LoVo cells shows EGFR pulls down endogenous LGR5. (D) CoIP shows enhanced LGR5 interaction with EGFR in LoVo cells after 15 min treatment with 5 μg/mL CTX. TL, total lysate. (E and F) Proximity ligation assays and quantification performed in (E) LIM1215 and (F) LoVo cells treated with vehicle or 5 μg/mL CTX. Statistical analysis was performed using two-tailed unpaired t test; ∗ p < 0.05; ∗∗ p < 0.01. Data presented as mean ± SD. Scale bars: 20 μm.

    Journal: Cell Reports Medicine

    Article Title: Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

    doi: 10.1016/j.xcrm.2025.102363

    Figure Lengend Snippet: EGFR interaction with LGR5 is enhanced by CTX (A and B) Co-immunoprecipitation (coIP) experiments with EGFR antibody or IgG isotype control shows that (A) recombinant LGR5 in 293T-LGR5 cells and (B) endogenous LGR5 in LoVo cells specifically interact with endogenous EGFR. (C) CoIP experiment with LGR5 mAb in LoVo cells shows EGFR pulls down endogenous LGR5. (D) CoIP shows enhanced LGR5 interaction with EGFR in LoVo cells after 15 min treatment with 5 μg/mL CTX. TL, total lysate. (E and F) Proximity ligation assays and quantification performed in (E) LIM1215 and (F) LoVo cells treated with vehicle or 5 μg/mL CTX. Statistical analysis was performed using two-tailed unpaired t test; ∗ p < 0.05; ∗∗ p < 0.01. Data presented as mean ± SD. Scale bars: 20 μm.

    Article Snippet: Chemical inhibitors, ligands, and siRNA used include: gefitinib (Cat# HY-50895); lapatinib (Cat# GW572016 ); nimotuzumab (Cat# HY-P9968); and U0126 (Cat# HY-12031A) from MedChemExpress; trametinib (Selleck Cat# GSK1120212); CHX (Selleck Cat#S7418); EGF (Gibco Cat# PMG8043); EGFR siRNA (Cell Signaling Technology Cat# 6480); MISSION negative control siRNA (Sigma Cat# SIC001).

    Techniques: Immunoprecipitation, Control, Recombinant, Ligation, Two Tailed Test